NM-2201 (also known as CBL-2201 and NA-5F-PIC[1]) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.

[6] It has been linked to serious adverse events in users.

[7] NM-2201 is specifically banned in Sweden,[8] Germany (Anlage II),[9] and Japan[10] but is also controlled in many other jurisdictions under analogue laws.

On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act.

[11] NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.